These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29268951)

  • 1. Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients.
    Liguori C; Mercuri NB; Stefani A; Pierantozzi M
    Sleep Med; 2018 Jan; 41():113-114. PubMed ID: 29268951
    [No Abstract]   [Full Text] [Related]  

  • 2. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
    Chazot PL
    Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
    Liguori C; Stefani A; Ruffini R; Mercuri NB; Pierantozzi M
    Parkinsonism Relat Disord; 2018 Dec; 57():80-81. PubMed ID: 30006034
    [No Abstract]   [Full Text] [Related]  

  • 4. ▼ Safinamide for Parkinson's disease.
    Drug Ther Bull; 2018 May; 56(5):54-57. PubMed ID: 29760163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safinamide (Xadago) for Parkinson's disease.
    Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
    Cattaneo C; Müller T; Bonizzoni E; Lazzeri G; Kottakis I; Keywood C
    J Parkinsons Dis; 2017; 7(4):629-634. PubMed ID: 28777756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safinamide in the treatment of Parkinson's disease.
    Schapira AH
    Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
    Cattaneo C; Kulisevsky J; Tubazio V; Castellani P
    Adv Ther; 2018 Apr; 35(4):515-522. PubMed ID: 29542008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safinamide for symptoms of Parkinson's disease.
    Müller T
    Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
    Bianchi MLE; Riboldazzi G; Mauri M; Versino M
    Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
    Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR
    Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safinamide for the treatment of Parkinson's disease.
    deSouza RM; Schapira A
    Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safinamide for the treatment of Parkinson's disease.
    Dézsi L; Vécsei L
    Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
    Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
    Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease.
    Rios Romenets S; Dauvilliers Y; Cochen De Cock V; Carlander B; Bayard S; Galatas C; Wolfson C; Postuma RB
    Parkinsonism Relat Disord; 2013 Jan; 19(1):92-4. PubMed ID: 22922159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on: Safinamide as adjunctive therapy for Parkinson's disease: A promising option with room for improvement.
    Matovu D
    J Neurol Sci; 2024 Jul; 462():123103. PubMed ID: 38925997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.